Evidence map›Paper›PMID 34768746›Full record

ArticleInternational journal of molecular sciences2021

MUG Mel3 Cell Lines Reflect Heterogeneity in Melanoma and Represent a Robust Model for Melanoma in Pregnancy.

Silke Schrom, Thomas Hebesberger, Stefanie Angela Wallner, Ines Anders, Erika Richtig, Waltraud Brandl, Birgit Hirschmugl, Mariangela Garofalo, Claudia Bernecker, Peter Schlenke and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 2 countries.

Silke SchromDivision of Biomedical Research, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0003-3795-6519
Thomas HebesbergerDivision of Biomedical Research, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-0725-8763
Stefanie Angela WallnerDivision of Biomedical Research, Medical University of Graz, 8036 Graz, Austria.
Ines AndersDivision of Biomedical Research, Medical University of Graz, 8036 Graz, Austria.
Erika RichtigDepartment of Dermatology, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-5505-6103
Waltraud BrandlDepartment of Obstetrics and Gynecology, Medical University of Graz, 8036 Graz, Austria.
Birgit HirschmuglDepartment of Obstetrics and Gynecology, Medical University of Graz, 8036 Graz, Austria.
Mariangela GarofaloDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35122 Padova, Italy.ORCID 0000-0002-5001-7826
Claudia BerneckerDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-5855-153X
Peter SchlenkeDepartment of Blood Group Serology and Transfusion Medicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-3271-3836
Karl KashoferDiagnostic and Research Institute of Pathology, Medical University of Graz, 8036 Graz, Austria.
Christian WadsackDepartment of Obstetrics and Gynecology, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-5589-8642
Ariane AigelsreiterDiagnostic and Research Institute of Pathology, Medical University of Graz, 8036 Graz, Austria.
Ellen HeitzerInstitute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, 8036 Graz, Austria.ORCID 0000-0002-8815-7859
Sabrina RiedlBioTechMed-Graz, 8010 Graz, Austria.
Dagmar ZweytickBioTechMed-Graz, 8010 Graz, Austria.
Nadine KretschmerInstitute of Pharmaceutical Sciences, Department of Pharmacognosy, University of Graz, 8010 Graz, Austria.
Georg RichtigDivision of Oncology, Medical University of Graz, 8036 Graz, Austria.
Beate RinnerDivision of Biomedical Research, Medical University of Graz, 8036 Graz, Austria.
Medical University of Graz · ATUniversity of Graz · ATUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanomas are aggressive tumors with a high metastatic potential and an increasing incidence rate. They are known for their heterogeneity and propensity to easily develop therapy-resistance. Nowadays they are one of the most common cancers diagnosed during pregnancy. Due to the difficulty in balancing maternal needs and foetal safety, melanoma is challenging to treat. The aim of this study was to provide a potential model system for the study of melanoma in pregnancy and to illustrate melanoma heterogeneity. For this purpose, a pigmented and a non-pigmented section of a lymph node metastasis from a pregnant patient were cultured under different conditions and characterized in detail. All four culture conditions exhibited different phenotypic, genotypic as well as tumorigenic properties, and resulted in four newly established melanoma cell lines. To address treatment issues, especially in pregnant patients, the effect of synthetic human lactoferricin-derived peptides was tested successfully. These new

Indexed as

AdultAnimalsCell Culture TechniquesCell LineCell Line, TumorFemaleHumansLactoferrinLymphatic MetastasisMelanomaMiceMice, Inbred NODPregnancyPrimary Cell CultureProto-Oncogene Proteins B-rafSkin Neoplasmslactoferricin BLactoferrinProto-Oncogene Proteins B-rafanti-tumor peptidesin vitro modelmelanomapregnancytumor heterogeneity

Identifiers

PMID34768746
PMCPMC8583216
OpenAlexW3207014252

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.